• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant

 

H1 Launches ‘Strategy as a Service’ Offering for Life Science Companies

by Jasmine Pennic 09/20/2018 Leave a Comment

H1 Launches ‘Strategy as a Service’ Offering for Life Science Companies

H1, a company helping healthcare organizations with live data insights to help fight diseases, today launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development.The company’s new DaVinci service begins at $10,000, which can help clients cut time-to-market in half, spans:- Market Landscape: Validate your strategy against an up-to-date, comprehensive picture of products and patient needs in your market.- Competitive
Read More

Accenture, Merck, Amazon Team Up to Launch Cloud-based Informatics Platform for Life Sciences

by Jasmine Pennic 09/17/2018 Leave a Comment

Accenture, Merck, Amazon Team Up to Launch Research Platform for Drug Development

In the Life Sciences research space, there has been a tendency to underinvest in technology. As a result, much of the current infrastructure is outdated, fragmented and unable to keep up with breakthroughs in modern science and technology.To help solve this technology challenge, Accenture, Merck and Amazon Web Services (AWS) are announcing a new, pre-competitive collaboration to launch a cloud-based informatics platform that will allow Life Sciences companies improve productivity, efficiency,
Read More

nference Raises $11M to Synthesize the World’s Biomedical Knowledge

by Fred Pennic 06/07/2018 Leave a Comment

nference Raises $11M to Synthesize the World’s Biomedical Knowledge

nference, a Cambridge, MA-based company on a mission to synthesize the exponentially growing biomedical knowledge has raised $11 million in Series A funding led by  Matrix Partners. The round also included participation from existing investor Matrix Capital Management. The company plans to utilize the funding to develop the company’s AI and R&D platforms, expand scientific operations in Cambridge MA and establish nference Labs in Bangalore, India.Founded by Murali Aravamudan and Venky
Read More

Vanderbilt University to Use $65M to Support Innovative Life Sciences Research

by Jasmine Pennic 03/30/2018 Leave a Comment

Deerfield Management and Vanderbilt University announced today the launch of Ancora Innovation, LLC ("Ancora"), a Deerfield company that will support Vanderbilt's innovative life science research and leverage Deerfield's expertise in accelerating state-of-the-art drug development. Ancora will fund projects with the aim of changing the current paradigm of drug development and establishing novel therapeutics to cure life-altering diseases.As part of Ancora, Deerfield will commit up to $65 million
Read More

AI-Driven Drug Discovery Startup twoXAR Lands $10M for Computational Platform

by Fred Pennic 03/19/2018 Leave a Comment

AI-Driven Drug Discovery Startup twoXAR Lands $10M for Computational Platform

twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, announced today that it has raised $10 million in Series A financing led by SoftBank Ventures including follow-on participation from seed investor Andreessen Horowitz. The biotech startup plans to use the funding to build the company’s drug pipeline through partnerships and accelerate preclinical development of existing candidates.   Traditional drug discovery and development is estimated to take 10-15 years and
Read More

Atomwise Raises $45M for Artificial Intelligence Platform for Drug Discovery

by Fred Pennic 03/07/2018 Leave a Comment

Atomwise Raises $45M for Artificial Intelligence Platform for Drug Discovery

Atomwise, a San Francisco, CA-based company that develops artificial intelligence systems for drug discovery has raised $45 million in Series A funding led by Monsanto Growth Ventures, B Capital Group and Data Collective. Prior investors Y Combinator, Khosla Ventures, and DFJ also participated in this Series A financing, along with new investors Baidu Ventures, Tencent, and Dolby Family Ventures. The oversubscribed round brings Atomwise’s total capital raised to more than $51 million.Founded in
Read More

Engine Biosciences Lands $10M for AI-Driven Drug Discovery Platform

by Jasmine Pennic 02/01/2018 Leave a Comment

Engine Biosciences Lands $10M for AI-Driven Drug Discovery Platform

Engine Biosciences("Engine"), a San Francisco, CA-based biotech company pioneering its artificial intelligence and genomics network biomedicine platform for drug discovery has raised $10 million. The seed round was co-led by by DHVC (Danhua Capital) and 6 Dimensions Capital, with participation from global biopharmaceutical leader WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI Harper, and Nest.Bio Ventures.The company plans to utilize the funding to support its proprietary platform,
Read More

Sanofi, TriNetX Partner to Optimize Clinical Trials with Digital Technology

by Jasmine Pennic 01/16/2018 Leave a Comment

Sanofi, TriNetX Partner to Optimize Clinical Trials with Digital Technology

TriNetX, the global health research network for healthcare organizations, biopharmaceutical companies, and Contract Research Organizations (CROs), announced their collaboration with their client, Sanofi, a global life sciences company committed to improving access to healthcare via the continuum of care.TriNetX/Sanofi Partnership DetailsClinical trials are a critical component of drug discovery and development, yet the time to market for drugs hasn’t improved significantly in nearly two decades.
Read More

Precision Medicine Group Raises $275M to Support Biomarker-Guided Drug Development

by Fred Pennic 12/21/2017 Leave a Comment

Precision Medicine Group

Precision Medicine Group (PMG), an integrated team of experts focused on biomarker-guided drug development has raised $275 million in funding led by Berkshire Partners and TPG Growth and also includes significant participation from Precision’s co-founders and management team as well as original investors Oak Investment Partners and J.H. Whitney. . This investment will support the expansion of PMG’s global footprint and provide additional scale to accelerate the development, approval and
Read More

Pfizer Spin Off Lands $103M to Develop New Drugs for Undeserved Patient Populations

by Fred Pennic 09/27/2017 Leave a Comment

SpringWorks Therapeutics Pfizer Spin Off Lands $103M to Develop New Drugs for Undeserved Patient Populations

SpringWorks Therapeutics, a new Pfizer spin-off launched as a way to advance investigational drug therapies that may hold significant promise for underserved patients has raised $103 million in funding in Series A funding. The Series A round was led by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer and LifeArc (formerly known as MRC Technology). SpringWorks Therapeutics’ collaborative business model is designed to deliver both social and financial returns via
Read More

  • Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 10
  • Go to page 11
  • Go to page 12
  • Go to page 13
  • Next Page

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |